

Supplement Materials.

Supplementary Table S1. Characteristics of survivors and non-survivors in patients with *P. jirovecii* pneumonia

Characteristics	Over all (n=112)	Survivor (n =62)	Non-survivor (n =50)	<i>p</i>
Comorbidity or underlying disease				
Cardiovascular disease	14 (12.5)	10 (16.1)	4 (8.0)	0.196
Cerebrovascular disease	11 (9.8)	8 (12.9)	3 (6.0)	0.340
Chronic kidney disease	20 (17.9)	12 (19.4)	8 (16.0)	0.645
Chronic lung disease	18 (16.1)	7 (11.3)	11 (22.0)	0.125
Diabetes	37 (33.0)	20 (32.3)	17 (34.0)	0.846
Heart failure	12 (10.7)	7 (11.3)	5 (10.0)	0.826
Hypertension	52 (46.4)	30 (48.4)	22 (44.0)	0.644
Liver disease	17 (15.2)	8 (12.9)	9 (18.0)	0.455
Connective tissue diseases	22 (19.6)	11 (17.7)	11 (22.0)	0.573
Solid cancer	43 (38.4)	26 (41.9)	17 (34.0)	0.391
Hematologic malignancy	21 (18.8)	13 (21.0)	8 (16.0)	0.503
Hematopoietic stem cell transplantation	5 (4.5)	2 (3.2)	3 (6.0)	0.655
Solid organ transplantation	6 (5.4)	5 (8.1)	1 (2.0)	0.222
Charlson Comorbidity Index score	5 (4-8)	5 (3-7)	5 (3-6)	0.436

Data are presented as median (interquartile range) or number (%).

These data exclude one patient whose treatment outcome was unknown due to transfer to another hospital during treatment.